Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population.

OBJECTIVES The Commonwealth of Massachusetts increased the copayment for prescription drugs by $1.50 for Medicaid (MassHealth) beneficiaries in 2003. We sought to determine the likely health outcomes and cost shifts attributable to this copayment increase using the example of inhaled corticosteroids (ICS) use among adult asthmatic Medicaid beneficiaries. METHOD We compared the predicted costs and health outcomes projected over a 1-year time horizon with and without the increase in copayment from the perspective of MassHealth, providers, pharmacies, and MassHealth beneficiaries by employing decision analysis simulation model. RESULTS In a target population of 17,500 adult asthmatics, increased copayments from 50 cent to $2.00 would result in an additional 646 acute events per year, caused by increased drug nonadherence. Annual combined net savings for the state and federal governments would be $2.10 million. Projected MassHealth savings are attributable to both decreased drug utilization and lower pharmacy reimbursement rates; these more than offset the additional costs of more frequent acute exacerbations. Pharmacies would lose $1.98 million in net revenues, MassHealth beneficiaries would pay an additional $0.28 million, and providers would receive additional $0.16 million. CONCLUSION Over its first year of implementation, increase in the prescription drug copayment is expected to produce more frequent acute exacerbations among asthmatic MassHealth beneficiaries who use ICS and to shift the financial burden from government to other stakeholders.

[1]  C. Reynolds.  Physician's Desk Reference , 2008 .

[2]  P. Cunningham.  Medicaid cost containment and access to prescription drugs. , 2005, Health affairs.

[3]  F. Gesten,et al.  Asthma in medicaid managed care enrollees residing in New York City: Results from a post-world trade center disaster survey , 2005, Journal of Urban Health.

[4]  A David Paltiel,et al.  A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. , 2004, Chest.

[5]  F. Gesten,et al.  A survey of Medicaid recipients with asthma: perceptions of self-management, access, and care. , 2004, Chest.

[6]  M. Knell,et al.  Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  J. Lexchin,et al.  Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence , 2004, International journal of health services : planning, administration, evaluation.

[8]  Dawn M Gencarelli.  Medicaid prescription drug coverage: state efforts to control costs. , 2003, NHPF issue brief.

[9]  Paula Lozano,et al.  Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. , 2002, The Journal of allergy and clinical immunology.

[10]  R. Kravitz,et al.  Does “mainstreaming” guarantee access to care for medicaid recipients with asthma? , 2001, Journal of General Internal Medicine.

[11]  Barrett T. Kitch,et al.  Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. , 2001, The Journal of allergy and clinical immunology.

[12]  J. Talbert,et al.  Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. , 2001, Health services research.

[13]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[14]  S. Thomas,et al.  Asthma hospitalizations and mortality in Chicago: an epidemiologic overview. , 1999, Chest.

[15]  R. Stanford,et al.  The cost of asthma in the emergency department and hospital. , 1999, American journal of respiratory and critical care medicine.

[16]  B. Stuart,et al.  Who bears the burden of Medicaid drug copayment policies? , 1999, Health affairs.

[17]  D. Himmelstein,et al.  Can Medicaid managed care provide continuity of care to new Medicaid enrollees? An analysis of tenure on Medicaid. , 1998, American journal of public health.

[18]  J. Newhouse.  Free for All?: Lessons from the RAND Health Insurance Experiment , 1993 .

[19]  R. N. Ross,et al.  A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma. , 1996, Clinical therapeutics.

[20]  J A Coventry,et al.  Emergency room encounters of pediatric patients with asthma: cost comparisons with other treatment settings. , 1996, The Journal of ambulatory care management.

[21]  L. Ried,et al.  Cost of asthma illnesses: emergency department visits without admission. , 1995, Pharmacy practice management quarterly.

[22]  S. G. Pollock.  Access of Medicaid recipients to outpatient care. , 1994, The New England journal of medicine.

[23]  P. Mayo,et al.  Demographic influences on asthma hospital admission rates in New York City. , 1994, Chest.

[24]  C. Normand,et al.  Free for All: Lessons from the RAND Health Insurance Experiment , 1994 .

[25]  J-P.A. Hobbs.  Free for all , 1994, Nature.

[26]  S. Soumerai,et al.  A critical analysis of studies of state drug reimbursement policies: research in need of discipline. , 1993, The Milbank quarterly.

[27]  W. Bailey,et al.  Asthma severity: a factor analytic investigation. , 1992, The American journal of medicine.

[28]  R. Parke,et al.  Statistical Abstract of the United States: 1984. , 1985 .

[29]  C E Reeder,et al.  The Effect of a Medicaid Drug Copayment Program on the Utilization and Cost of Prescription Services , 1984, Medical care.

[30]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  P. DeFazio.  The Congress of the United States , 1906, Science.

[32]  D. Rousseau,et al.  MEDICAID ENROLLME NT IN 50 STATES , 2005 .

[33]  K. Levit,et al.  Trends in U.S. health care spending, 2001. , 2003, Health affairs.

[34]  E. Rahme,et al.  Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance. , 2003, Health policy.

[35]  Barrett T. Kitch,et al.  A novel approach to defining the relationship between lung function and symptom status in asthma. , 2002, Journal of clinical epidemiology.

[36]  Barrett T. Kitch,et al.  FEV(1) is associated with risk of asthma attacks in a pediatric population. , 2001, The Journal of allergy and clinical immunology.

[37]  C. Bessinger.  Access of Medicaid recipients to outpatient care. , 1994, The New England journal of medicine.

[38]  E. Schor.  The Henry J. Kaiser Family Foundation. , 1990, Academic medicine : journal of the Association of American Medical Colleges.

[39]  D. Birnbaum,et al.  Technology assessment. , 1989, Journal of healthcare materiel management.

[40]  J. Newhouse,et al.  Copayments and Demand for Medical Care : The California Medicaid Experience. , 1978 .

[41]  D. Commerce.  Statistical abstract of the United States , 1978 .